Intravitreal Brolucizumab for Neovascular Age-Related Macular Degeneration in a Vitrectomized Eye

The efficacy of intravitreal anti-VEGF may be reduced in vitrectomized eyes due to accelerated drug clearance. Given its longer durability, brolucizumab may represent a suitable therapeutic option. However, its efficacy in vitrectomized eyes remains to be explored. Herein, we describe the management...

Descripción completa

Detalles Bibliográficos
Autores principales: Maggio, Emilia, Alfano, Alessandro, Mete, Maurizio, Pertile, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944215/
https://www.ncbi.nlm.nih.gov/pubmed/36845453
http://dx.doi.org/10.1159/000526568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9944215/
https://www.ncbi.nlm.nih.gov/pubmed/36845453
http://dx.doi.org/10.1159/000526568

Ejemplares similares